Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.

As for dynamic EBV titers, the Mayo Clinic Phase 2 Consortium study of nivolumab in RM-NPC observed a decreasing trend in EBV DNA titers in 87.5% of the responders, but found no association of plasma EBV DNA clearance with response rate and survival in RM-NPC patients receiving nivolumab [ 3 ].

also in 47,180 other papers